HARVARD BIOSCIENCE INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $86.5M | $94.1M | $112.2M | $113.3M | $118.9M |
| Cost of revenue | $36.6M | $39.4M | $46.2M | $52.5M | $51.3M |
| Gross profit | $49.9M | $54.8M | $66.1M | $60.8M | $67.7M |
| Research and development | $8.8M | $10.4M | $11.8M | $12.3M | $10.8M |
| Operating expenses | $98.5M | $61.0M | $64.2M | $67.8M | $65.6M |
| Operating income | -$48.6M | -$6.2M | $1.9M | -$6.9M | $2.1M |
| Pretax income | -$57.4M | -$11.7M | -$2.6M | -$9.2M | -$140,000 |
| Income tax expense | -$686,000 | $740,000 | $859,000 | $337,000 | $148,000 |
| Net income | -$56.7M | -$12.4M | -$3.4M | -$9.5M | -$288,000 |
| Balance Sheet | |||||
| Cash and equivalents | $8.6M | $4.1M | $4.3M | $4.5M | $7.8M |
| Current assets | $48.2M | $45.1M | $49.0M | $51.1M | $61.6M |
| Total assets | $80.1M | $126.6M | $137.4M | $145.4M | $162.3M |
| Current liabilities | $22.0M | $55.0M | $26.5M | $23.2M | $25.3M |
| Total liabilities | $66.3M | $63.3M | $64.3M | $73.1M | $78.9M |
| Total debt | $40.0M | — | $37.1M | $47.7M | $49.5M |
| Stockholders' equity | $13.7M | $63.3M | $73.1M | $72.2M | $83.4M |
| Cash Flow Statement | |||||
| Cash from operations | $6.7M | $1.4M | $14.0M | $1.2M | $1.3M |
| Depreciation and amortization | $1.7M | $1.7M | $1.5M | $1.5M | $1.8M |
| Stock-based compensation | $1.9M | $4.3M | $5.0M | $4.4M | $4.2M |
| Capital expenditure | $1.3M | $2.6M | $1.8M | $1.6M | $1.2M |
| Free cash flow | $5.5M | -$1.2M | $12.2M | -$438,000 | $67,000 |
| Impairments | $48.0M | $0 | $0 | $0 | $0 |
Shares outstanding 4.5M
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.